CD99 and Ewing sarcoma: Baldauf et al. (2018) found out that the EWSR1-ETS-targeted genes—BCL11B and GLG1—are driven by SEs through immunohistochemistry analysis. They found that both BCL11B and GLG1 are more specific than CD99 for Ewing sarcoma, suggesting that BCL11B and GLG1 can be used as novel biomarkers for the diagnosis of Ewing sarcoma. Therefore, the discovery of BCL11B and GLG1 may significantly reduce the number of misdiagnosed patients, thereby improving the care of patients with Ewing sarcoma.